Arcutis Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Revenue	59.61	3.69	0	0	0	0	0
Revenue Growth (YoY)	1517.09%	-	-	-	-	-	-
Cost of Revenue	4.99	0.75	0	0	0	0	0
Gross Profit	54.62	2.93	0	0	0	0	0
Selling, General & Admin	185.15	122.12	60.97	21.34	6.61	1.8	0.7
Research & Development	110.58	182.44	145.56	115.31	36.52	17.94	3.41
Operating Expenses	295.72	304.56	206.53	136.65	43.13	19.74	4.11
Operating Income	-241.1	-301.63	-206.53	-136.65	-43.13	-19.74	-4.11
Interest Expense / Income	29.71	15.65	0	0	0	0	0
Other Expense / Income	-11.79	-5.82	-0.17	-0.97	-1.14	-0.48	0.87
Pretax Income	-259.03	-311.46	-206.36	-135.68	-42	-19.26	-4.98
Income Tax	3.11	0	0	0	0	0	0
Net Income	-262.14	-311.46	-206.36	-135.68	-42	-19.26	-4.98
Shares Outstanding (Basic)	69	55	49	36	2	1	1
Shares Outstanding (Diluted)	69	55	49	36	2	1	1
Shares Change	25.94%	11.39%	38.51%	1835.11%	48.68%	78.29%	-
EPS (Basic)	-3.78	-5.66	-4.18	-3.80	-22.78	-15.53	-7.16
EPS (Diluted)	-3.78	-5.66	-4.18	-3.80	-22.78	-15.53	-7.16
Free Cash Flow	-247.49	-258.05	-175.62	-113.35	-43.13	-14.09	-3.78
Free Cash Flow Per Share	-3.57	-4.69	-3.56	-3.18	-23.40	-11.36	-5.43
Gross Margin	91.63%	79.54%	-	-	-	-	-
Operating Margin	-404.49%	-8183.04%	-	-	-	-	-
Profit Margin	-439.79%	-8449.76%	-	-	-	-	-
Free Cash Flow Margin	-415.20%	-7000.76%	-	-	-	-	-
EBITDA	-227.43	-294.55	-205.59	-135.22	-41.8	-19.26	-4.98
EBITDA Margin	-381.56%	-7991.13%	-	-	-	-	-
Depreciation & Amortization	1.88	1.25	0.76	0.46	0.2	0	0
EBIT	-229.32	-295.81	-206.36	-135.68	-42	-19.26	-4.98
EBIT Margin	-384.72%	-8025.12%	-	-	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).